AstraZeneca

Phase III Trial Shows Baxdrostat Significantly Lowers Blood Pressure in Hard-to-Treat Hypertension

WILMINGTON, DE — New data from the BaxHTN Phase III trial indicate that baxdrostat, an investigational aldosterone synthase inhibitor, achieved significant reductions in systolic blood pressure among patients with uncontrolled …

Phase III Trial Shows Baxdrostat Significantly Lowers Blood Pressure in Hard-to-Treat Hypertension Read More